Company ProfilePremium

Pa Shun International Holdings Limited

Company Profile Analysis

百信國際控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Pa Shun International Holdings Limited - Company showcase

Year Founded & Workforce

2011

108 Employees

Pa Shun International Holdings Limited logo

Pa Shun International Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Pa Shun International Holdings Limited Overview

FieldDetailSource
Legal namePa Shun International Holdings Limited (百信國際控股有限公司)FY2025 annual results announcement (30 Mar 2026)
Former namePa Shun Pharmaceutical International Holdings Limited; renamed June 2017Company profile (StockAnalysis); irasia.com listing page
Incorporated3 May 2011, Cayman Islands, exempted company with limited liabilityFY2025 results announcement, Note 1
ListingMain Board, SEHK, 19 June 2015 (IPO of 250 million shares at HK$1.22)FY2025 results, Note 1; Moomoo company profile
Stock code / ISIN0574 (HKEX) / KYG693781000HKEX filings; Moomoo profile
CUSIPNot applicable / not publicly disclosed—
Registered officeCricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111FY2025 results, Note 1
HK principal place of businessSuites 2601–2603, 26/F, Shui On Centre, 6–8 Harbour Road, Wanchai, Hong KongFY2025 results, Note 1
PRC principal place of businessNo. 608–616, Building 28, Longfor North Paradise Walk 2, 229 Wufuqiao East Road, Jinniu District, Chengdu, SichuanFY2023 Annual Report, Corporate Information
Fiscal year end31 DecemberFilings
Presentation currencyRMB (the company's own functional currency is HK$)FY2025 results, Note 2
Employees108 (31 Dec 2025); 97 (2024); 90 (2023); 92 (2022)FY2025 results; FY2024 results; FY2023 AR
Auditor (current)Forvis Mazars CPA Limited (FY2024, FY2025); previously CCTH CPA Limited (appointed 11 Jan 2017; audited through FY2023)FY2025 results; FY2023 AR
Latest audit opinion (FY2025)Unmodified, with a material uncertainty related to going concern paragraphFY2025 results, auditor's report extract
Shares in issue1,474,992,908 at 31 Dec 2025. About 1,990,576,062 after the June 2026 rights issue (515,583,154 rights shares allotted)FY2025 results; rights-issue results announcement (17 Jun 2026)
Last traded priceHK$0.018 (last close before suspension on 2 Jul 2026)StockAnalysis (30 Jun 2026 close); etnet quote page
Market capitalisationAbout HK$35.8 million on post-rights share count (derived: 1,990.6m × HK$0.018). StockAnalysis shows HK$26.55 million using the pre-rights 1.47bn share count — discrepancy notedDerived; StockAnalysis
Trading statusSuspended since 09:00, 2 July 2026Resumption-guidance announcement (16 Jul 2026)
Controlling shareholderMr. Chen Yenfei (陳燕飛), via Praise Treasure Limited (嘉寶有限公司) plus a direct holding. About 1,143.12m shares (≈57.4% derived) after the rights issue. 753.04m of these shares are pledged and subject to a receivershipRights-issue results (17 Jun 2026); FY2023 AR
Websitehttp://www.pashun.com.cn (also www.pashun.cn)Filings

The identification details supplied match the current listed entity. The ticker (0574.HK), ISIN (KYG693781000) and website (pashun.com.cn) are unchanged. The company also uses www.pashun.cn as its investor-relations domain in FY2024–FY2025 results announcements. No change of listing venue has occurred.

Pa Shun International Holdings is a Cayman-incorporated, Hong Kong-listed micro-cap. Its operating business is a small pharmaceutical distribution and manufacturing operation based in Chengdu, Sichuan Province, PRC. The Group reported revenue of RMB86.8 million in FY2025. About 83% came from distributing third-party pharmaceuticals, to wholesalers and to hospitals and medical institutions in rural areas. The remaining 17% came from selling drugs it manufactures in Sichuan. Once a far larger business (RMB845 million revenue in FY2019), the Group has spent five years in a cycle of losses, impairments, bond defaults, trading suspensions, a court-sanctioned creditor scheme (effective March 2024) and a discounted rights issue. It now faces the loss of its operating subsidiaries to secured-creditor receivers and a pending winding-up petition. Its competitive relevance in China's RMB2.6-trillion-plus drug distribution market is negligible. The investment case today is purely a restructuring and recovery-value question rather than an operating one.


Company's own description (FY2025 annual results, paraphrased)

The company describes itself as an investment holding company. Its subsidiaries are principally engaged in pharmaceutical distribution and the manufacture of pharmaceutical products in the PRC. Since FY2023, management has organised and reported the business by business line and distribution channel, as two reportable segments:

Pharmaceutical distribution: Sale of pharmaceutical products to (i) wholesalers and (ii) hospitals and other medical institutions in rural areas.

Pharmaceutical manufacturing: Sale of pharmaceutical products manufactured by the Group.

Revenue is recognised at a point in time on delivery of goods. The chief operating decision makers (the executive directors) assess segments only on revenue and gross profit. No segment asset or liability analysis is provided to them (FY2025 results, Note 3).

In the FY2023 Corporate Governance Report, the company stated a vision of becoming a leading pharmaceutical company by building on its foundation in the PRC (paraphrased).

Independent characterisation

Customer typeFY2025 revenue (CNY K)Share of revenue
Wholesalers (distribution)42,42748.9%
Rural hospitals and other medical institutions (distribution)29,26233.7%
Purchasers of self-manufactured products (manufacturing, external)15,11817.4%
Total86,807100%

Business model. Pa Shun is essentially a regional, sub-scale pharmaceutical trading house with a small captive manufacturing plant. In distribution, it buys drugs from manufacturers and resells them on credit terms of 30–180 days. Its margin is the spread between supplier and customer prices. A key feature is the "agricultural" or rural channel: sales to county- and township-level hospitals and clinics. That channel depends on winning provincial or municipal government tenders for drug supply authority (FY2023 AR, Risk Factors). The manufacturing arm produces generic or traditional products in Sichuan. Its pricing has been cut by inclusion in China's National Centralised Drug Procurement (volume-based procurement, "VBP") programme in 2025 (FY2025 MD&A).

Revenue model mix. 100% product sales (goods), recognised at point in time. There is no service, subscription or licensing revenue. Minor "other income" comes from short-term lease rental (RMB0.9 million in FY2025) and amortisation of government grants (RMB0.5 million) (FY2025 results, Note 4).

Value chain position. The Group is mid-stream, as a distributor and wholesaler. It also has a small upstream manufacturing presence. It has no retail presence today. A self-operated retail pharmacy segment was reported historically (Moomoo company profile lists three segments: distribution, self-operated retail pharmacies and manufacturing). The FY2023 Annual Report lists only two segments; the date the retail segment ceased is not disclosed in the filings reviewed.

Customer types (FY2025).

Source: FY2025 results, Note 3(b)(i): Customer concentration is extreme.

  • In FY2025, Customer C contributed RMB12.1m (14.0%) and Customer D RMB9.5m (10.9%).

  • In FY2024, a single manufacturing customer (Customer A) contributed RMB19.4m (22.4%) and Customer B RMB10.5m (12.1%). Customer A fell below the 10% threshold in FY2025, which coincides with the 41% drop in manufacturing revenue.

  • In FY2023, the top five customers took 59.8% of sales. The top five suppliers provided 73.2% of purchases, and the single largest supplier 43.3% (FY2023 AR, Report of Directors).

End markets. The PRC only. The company states that 100% of segment revenue and results derive from the PRC (FY2025 results, Note 3(b)(iv)). Operations are concentrated in Sichuan Province. The FY2023 AR notes that the main production facilities are all located in Chengdu and Sichuan.

Current operational status (critical). On 2 July 2026, receivers were appointed over the assets of the intermediate holding company of the PRC subsidiaries. The company's 30 September 2026 quarterly update states that these PRC subsidiaries together account for 100% of Group revenue. It also says the company could not adequately access their books and records in time to publish 2026 interim results.

Strategy

Stated strategy themes (paraphrased from FY2023–FY2025 filings)

  1. Production and distribution capability. Management repeatedly states it will focus on improving production and distribution capabilities to capture opportunities from a market recovery. This appears in the outlook sections of the FY2023, FY2024 and FY2025 MD&A.

  2. Competitive-market framing. In FY2024 and FY2025, management characterises the PRC economy as in a phase of slower, steady development, and expects pharmaceutical wholesale and consumer markets to become more competitive and challenging.

  3. Portfolio expansion. The Group says it continues to expand its product portfolio to meet new customer demands (FY2025 going-concern measures). Ten new distribution licences were secured in FY2023.

  4. Cost control. Management is tightening operating-expense controls and seeking new business opportunities (FY2025 going-concern measures). Selling expenses fell 42% in FY2025.

  5. Balance sheet repair. Measures include the debt restructuring (2023–24 Scheme of Arrangement), refinancing and extension of borrowings, possible pledging of assets (right-of-use assets, property project), and new share issuance (FY2025 going-concern measures; executed as the June 2026 rights issue).

  6. Acquisitions and alliances. The FY2023 AR risk section lists "continue to seek for acquisition and alliance" as a strategy. Given the Malaysian episode, this was paired with new investment-management controls.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateTarget / detailStatusSource
Scheme of Arrangement execution2024–2028Annual cash payments of the higher of HK$5m (2024) / HK$10m (2025–2028) or a share of net profits; shares to be issued for any shortfall2024 payment funded from seized deposit; repayment terms still under negotiation. Default reportedly linked to the July 2026 receivershipFY2025 results Note 12; third-party summary of 2 Jul 2026 announcement
Cost-reduction programmeFY2025Selling expenses down 42.2%AchievedFY2025 MD&A
Borrowing extensionsFY2025 – Q1 2026RMB19m other borrowings extended; RMB12m bank renewed; RMB10.4m new; RMB5.4m renewed post year-end; RMB13.5m third-party support commitmentExecutedFY2025 going-concern note
1-for-2 non-underwritten rights issueProposed 16 Apr 2026; prospectus 11 May 2026; unconditional 10 Jun 2026515,583,154 rights shares issued (69.91% take-up). Gross about HK$6.99m, net about HK$6.49m, entirely for partial loan repayment. Unsubscribed shares under the compensatory placing: none placedCompletedRights-issue results (17 Jun 2026)
General mandate to repurchase up to 10%Proposed for 30 Jun 2026 AGMUp to 221,248,936 shares post-rightsRoutine; no buyback executeditiger summary of 8 Jun 2026 circular
Resumption planFrom 14 Jul 2026Must satisfy four HKEX conditions by 1 Jan 2028In progress; no resumption plan timetable published as of 30 Sep 202630 Sep 2026 update
ESG commitments—Reduce electricity use; recycle office materialsGeneric; no targetsFY2023 AR

Medium-term financial targets / guidance

None. The company has not published revenue, margin or leverage targets. There is no investor day and no earnings-call transcript.

Products & Services

Disclosure limitation. The annual results, annual report extracts and interim announcements reviewed do not name individual products, brands, dosage forms, therapeutic categories or approval numbers. A product-by-product catalog is therefore not publicly disclosed in the reviewed sources. What can be stated with evidence is summarised below.

Analytical inference (flagged as inference, not disclosure). The background of the manufacturing head points to traditional Chinese medicine or generics production rather than innovative drugs. Li Xiaoduo graduated in traditional Chinese medicine from Chengdu College of TCM and previously worked as a biotech workshop supervisor. The near-zero R&D disclosure points the same way. VBP inclusion also indicates multi-source generic products.

Product Portfolio

SegmentOfferingWhat is disclosedTarget customerPricing modelSource

Distribution

Third-party pharmaceutical products (wholesale)

Products sourced from manufacturers and resold. Specific products not named

PRC pharmaceutical wholesalers

Spread-based; 30–180 day credit terms

FY2025 results, Notes 3 and 10

Distribution

Third-party pharmaceutical products (rural "agricultural" channel)

Sold to hospitals and medical institutions in rural areas after the Group wins provincial or municipal supply tenders

County, township and rural hospitals and clinics

Tender or government-procurement pricing

FY2023 AR, Risk Factors

Distribution

10 newly licensed distribution products (FY2023)

Distribution rights to 10 new products secured in 2023; names not disclosed

Hospital customers

—

FY2023 AR, MD&A

Manufacturing

Self-manufactured pharmaceutical products

Produced at Chengdu and Sichuan facilities under PRC GMP (2010 revision). A "substantial portion" was included in the 2025 National Centralised Drug Procurement programme

Distributors and institutions; one anchor customer in FY2024

VBP-set prices for procured items; otherwise not disclosed

FY2025 MD&A; FY2023 AR

Historical

Self-operated and franchised retail pharmacies

A retail pharmacy segment and franchising entities are referenced in historic disclosures

Retail consumers

Retail

Moomoo profile; FY2023 AR risk section (mentions "self-operating or franchising entities")

Non-core

Property development project (Chengdu)

Stalled construction project carried at RMB39.9m after cumulative impairments exceeding RMB150m

n/a (asset held)

—

FY2025 results; FY2023 AR

Non-core

Short-term property leasing

Rental income RMB0.9m (FY2025)

Third-party lessees

Lease

FY2025 results, Note 4

“—” = not publicly disclosed.

Financial Narrative

All figures RMB million; fiscal years end 31 December. FY2021–FY2023 are from the FY2023 Annual Report Financial Summary and MD&A. FY2023 balance sheet comparatives follow the FY2024 results announcement. FY2024–FY2025 are from the FY2025 and FY2024 annual results announcements. FY2022 cost-line detail is from the FY2023 AR MD&A.

Income statement

Revenue CAGR. FY2021→FY2025: +0.3% p.a. (derived). FY2019→FY2025: –31.6% p.a. (derived from RMB845.4m to RMB86.8m).

Material non-recurring and non-cash items affecting reported earnings (RMB M)

Sources: FY2023 AR MD&A (FY2021–FY2022 impairments); FY2024 and FY2025 results.

Commentary — income statement

Revenue collapse and plateau. The Group's top line fell by about 90% between FY2019 and FY2021. That period spanned the COVID-19 disruption, the 2019 controlling-shareholder share-pledge crisis and the apparent exit from retail pharmacy. FY2023's rebound to RMB129.4m was attributed to post-COVID normalisation and 10 new distribution licences. It proved temporary: revenue fell back to about RMB86–87m in FY2024–FY2025, which looks like the business's current run-rate.

Gross margin erosion is the key FY2025 inflection. Gross margin fell from 22.6% (FY2023) to 19.7% (FY2024) to 13.8% (FY2025). Management attributes FY2025 to VBP price cuts. Segment data show an equally important channel mix shift toward 4%-margin wholesaler sales. Gross profit of RMB12.0m in FY2025 no longer covers cash overheads: selling plus administrative costs were RMB19.2m.

Cost control is real but insufficient. Selling expenses were cut 42% in FY2025 (advertising fell from RMB2.6m to RMB0.7m). Administrative costs have been held at about RMB14.5m since the FY2023 legal and restructuring spike of RMB23.6m.

Finance costs now consume the business. Finance costs of RMB15.0m in FY2025 exceed gross profit. RMB11.4m of this is non-cash imputed interest unwinding the zero-coupon scheme obligation at a 7.32% effective rate. Cash interest on bank and other borrowings was about RMB3.6m.

Earnings quality is low. FY2023's only profit (RMB2.4m) depended on RMB22.9m of net ECL reversals. FY2025's derived operating loss was held near breakeven (–RMB0.6m) only by an RMB11.6m reversal of trade-receivable ECL. Stripping out ECL movements and impairments, FY2025 underlying EBIT was about –RMB5.8m (derived: 12.0 + 1.3 – 4.6 – 14.6).

Balance sheet

Notes: - Short-term debt (derived) = bank borrowings + current other borrowings + current scheme obligations + current corporate bonds.

  • FY2023 current liabilities are shown as restated in FY2024 comparatives (RMB248.3m). The FY2023 AR shows RMB247.7m.

  • Excluded from debt: deferred government grants (RMB21.0m, non-cash), amounts due to shareholders and related parties (RMB1.2m), and the RMB4.5m payable to the Scheme Administrator (classified in trade and other payables).

  • Gross trade receivables of RMB298.8m carry a RMB246.6m (82.5%) ECL allowance. RMB28.0m of the net balance is aged over six months (FY2025 Note 10).

Cash flow

Operating cash flow figures are from the going-concern notes (FY2024 and FY2025 results). Capex is not disclosed in the announcements reviewed. The company states it did not purchase, sell or redeem listed securities in FY2023–FY2025.

Financing activity (FY2025, from the going-concern note).

  • Other borrowings of about RMB19.0m extended by 1–1.5 years.

  • Bank borrowings of about RMB12.0m renewed for one year.

  • New bank and other borrowings of about RMB10.4m raised.

After the balance-sheet date.

  • RMB5.4m of borrowings renewed.

  • A commitment obtained from an independent third party to provide about RMB13.5m of financial support as needed.

  • The June 2026 rights issue raised gross HK$6.99m (net HK$6.49m), earmarked entirely for partial loan repayment.

Ratios

ROE, ROIC and debt-to-equity are not meaningful because equity has been negative since FY2021. The current ratio is company-reported for FY2022–FY2025; FY2021 is derived. EBITDA used for leverage includes ECL reversals and impairments, so underlying leverage is effectively infinite.

Trend commentary

  1. Solvency. The Group has been balance-sheet insolvent (net liabilities) for five consecutive year-ends, and the deficit is widening by about RMB12–20m per year.

  2. Liquidity inflection. The 2024 scheme briefly pushed the current ratio above 1.0x by reclassifying debt to non-current. By FY2025 it was back to 0.85x with only RMB5.5m of cash.

  3. Working-capital deterioration. FY2025 net trade receivables doubled to RMB52.2m and RMB28.0m is now aged beyond six months. Most of the FY2025 RMB11.6m ECL reversal was booked in distribution, while gross receivables actually rose. Taken together, these points warrant scepticism about the receivable carrying values.

  4. Scheme obligations dominate the capital structure. The obligation of RMB160.2m is 78% of total debt (derived). Its maturity profile is back-ended: RMB143.3m falls due in years 2–5, consistent with share issuance to scheme creditors around 2028 if cash payments fall short.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Distribution revenue, external (CNY Mn)

107.060.971.7

Distribution to wholesalers (CNY Mn)

—21.942.4

Distribution to rural hospitals and institutions (CNY Mn)

—38.929.3

Manufacturing revenue, external (CNY Mn)

22.425.715.1

Manufacturing inter-segment revenue (CNY Mn)

—1.11.1

Total Group revenue (CNY Mn)

129.486.686.8

Distribution segment profit, gross profit basis (CNY Mn)

—7.45.8

Manufacturing segment profit, gross profit basis (CNY Mn)

—9.66.2

Distribution segment margin (%)

—12.28.1

Manufacturing segment margin on total segment revenue (%)

—36.038.2

Distribution revenue YoY growth (%)

—-43.117.7

Manufacturing revenue YoY growth (%)

—14.6-41.1

Distribution share of Group revenue (%)

82.770.382.6

Manufacturing share of Group revenue (%)

17.329.717.4

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

85.971.8129.486.686.8

Revenue YoY growth (%)

-81.9-16.480.3-33.10.3

Cost of goods sold (CNY Mn)

—58.5100.169.574.8

Gross profit (CNY Mn)

—13.329.317.112.0

Gross margin (%)

—18.522.619.713.8

Selling and distribution expenses (CNY Mn)

—6.07.28.04.6

Administrative and other operating expenses (CNY Mn)

—12.823.614.514.6

Finance costs (CNY Mn)

—10.612.914.815.0

Operating income, derived as PBT plus finance costs (CNY Mn)

—-32.616.3-0.2-0.6

D&A, derived as PP&E plus ROU plus intangibles (CNY Mn)

——3.33.13.2

EBITDA, derived (CNY Mn)

——19.62.92.5

Pre-tax profit (CNY Mn)

-323.4-43.23.4-15.0-15.7

Income tax (CNY Mn)

-7.0-0.2-1.1-0.3-0.2

Net income attributable (CNY Mn)

-330.4-43.42.4-15.3-15.9

EPS basic (MYR Bn cents)

-22.40-2.940.16-1.04-1.07

EPS diluted (MYR Bn cents)

-22.40-2.940.16-1.04-1.07

Dividend per share (MYR Bn cents)

00000

Operating margin, derived (%)

—-45.412.6-0.2-0.7

EBITDA margin, derived (%)

——15.23.32.9

Net margin (%)

-384.6-60.41.8-17.7-18.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Impairment on property development project (CNY Mn)

-111.8-17.0-9.0-4.5-3.6

Net ECL reversal (provision) on trade receivables (CNY Mn)

——20.23.811.6

Net ECL (provision) reversal on other receivables (CNY Mn)

——2.7-5.0-1.4

Impairment (reversal) on prepayments and deposits (CNY Mn)

——1.2-8.2-1.3

Gain on restructuring of financial liabilities (CNY Mn)

00017.60

Imputed interest on Scheme obligations (CNY Mn)

0008.911.4

Balance Sheet — Total assets

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

167.2136.1206.6179.6169.7

Non-current assets (CNY Mn)

115.594.982.374.869.2

of which property development project (CNY Mn)

74.057.048.043.539.9

of which property, plant and equipment (CNY Mn)

——32.429.527.5

Current assets (CNY Mn)

51.841.2124.3104.9100.5

Inventories (CNY Mn)

——5.437.819.7

Trade receivables, net of ECL (CNY Mn)

——27.026.152.2

Gross trade receivables before ECL (CNY Mn)

——289.0284.3298.8

Prepayments and deposits paid (CNY Mn)

——65.321.416.7

Cash and cash equivalents (CNY Mn)

—1.916.516.05.5

Current liabilities (CNY Mn)

200.6227.2248.3103.5117.9

Non-current liabilities (CNY Mn)

25.124.474.4212.2199.8

Bank borrowings (CNY Mn)

—4.57.211.419.0

Other borrowings (CNY Mn)

—21.375.332.626.5

Corporate bonds payable (CNY Mn)

——83.500

Scheme of Arrangement obligations (CNY Mn)

000163.7160.2

Total debt incl. Scheme obligations, derived (CNY Mn)

——166.0207.7205.7

Short-term debt, derived (CNY Mn)

——115.022.034.5

Long-term debt, derived (CNY Mn)

——50.9185.8171.3

Net debt, derived (CNY Mn)

——149.5191.8200.2

Goodwill and intangibles (CNY Mn)

——0.030.010

Working capital (CNY Mn)

-148.8-186.0-124.01.3-17.4

Total equity / (net deficit) (CNY Mn)

-58.5-115.5-116.1-136.0-148.0

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

———-1.7-10.1

Dividends paid (CNY Mn)

00000

Share buybacks (CNY Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROA on average total assets, derived (%)

-98.6-28.61.4-7.9-9.1

Current ratio (x)

0.260.180.501.010.85

Net debt to EBITDA, derived (x)

——7.666.180.1

Interest coverage, EBIT over finance costs, derived (x)

—-3.11.26-0.01-0.04

Asset turnover on average assets, derived (x)

0.260.470.760.450.50

Days sales outstanding, period-end net, derived (days)

——76.2110.2219.6

Days inventory outstanding, derived (days)

——19.6198.795.9

Days payables outstanding, trade and bills, derived (days)

——118.9166.1138.2

Cash conversion cycle, derived (days)

——-23.1142.8177.3

Revenue by Region and Region Margins & Growth (%)

MetricFY2023FY2024FY2025

PRC revenue (CNY Mn)

129.486.686.8

PRC revenue YoY growth (%)

80.3-33.10.3

PRC share of Group revenue (%)

100100100

Hong Kong and other regions revenue (CNY Mn)

000

Revenue by Region

MetricFY2023FY2024FY2025

PRC distribution to wholesalers (CNY Mn)

—21.942.4

PRC distribution to rural institutions (CNY Mn)

—38.929.3

PRC manufacturing, external (CNY Mn)

22.425.715.1

Valuation Snapshot

MetricValueSource

Last price

HK$0.018 (last close before 2 Jul 2026 suspension)

StockAnalysis; etnet

52-week range (to 30 Jun 2026)

HK$0.016 – HK$0.097

StockAnalysis

Shares in issue

About 1,990.6m post-rights (1,474,992,908 pre-rights)

Derived; FY2025 results

Market cap

About HK$35.8m (derived, post-rights) / HK$26.55m (StockAnalysis, pre-rights count)

Derived; StockAnalysis

Beta

-0.31

StockAnalysis

IPO price (2015)

HK$1.22

Moomoo profile

Rights issue price

About HK$0.0136 implied (HK$6.99m ÷ 515.58m shares). etnet lists HK$0.014

Derived; etnet

Analyst coverage

None (0 analysts)

Simply Wall St; StockAnalysis

Share Count (millions)

MetricFY2021FY2022FY2023FY2024FY2025

Weighted average shares, basic (millions)

——1,475.01,475.01,475.0

Year-end shares in issue (millions)

1,475.01,475.01,475.01,475.01,475.0

Share Price & Returns

Reference pointPrice / implied priceSource

IPO, Jun 2015

HK$1.22

Moomoo

Late Apr 2025 (suspension)

Implied about HK$0.037 (market cap HK$54.57m ÷ 1.475bn shares)

TipRanks

Aug 2025

Implied about HK$0.057 (market cap HK$84.07m)

TipRanks

Apr 2026

About HK$0.046

etnet

8 Jun 2026

HK$0.037

irasia.com

30 Jun 2026

HK$0.018

StockAnalysis

Valuation Multiples

MultiplePa Shun

P/E

n/m (loss-making)

P/B

n/m (negative equity of RMB148.0m)

EV (CNY Mn)

About 233 (market cap about 33 + net debt 200.2)

EV/Sales

About 2.7x

EV/EBITDA

About 93x (on derived EBITDA of RMB2.5m, which includes ECL reversals)

Capital Markets

ItemDetail

Dividend history

No dividends declared for FY2021–FY2025. Distributable reserves were nil at 31 Dec 2023 (accumulated losses RMB766.9m vs share premium RMB691.9m at company level)

Dividend policy

Board discretion based on results, cash flow, financial condition and legal restrictions (FY2023 AR)

Buyback authorisation

General mandate up to 10% proposed for the 30 Jun 2026 AGM (up to 221,248,936 shares); none executed FY2023–FY2025

Credit ratings

None. Not rated by Moody's, S&P or Fitch

Corporate bonds

HK$113.9m issued in 2016–18 at 6.5–7%; defaulted; restructured into the Scheme in 2024

Capital Markets — Scheme obligations

MetricWithin 1 year1–2 years2–5 years

Scheme obligations (CNY Mn)

8.88.2143.3

Bank borrowings (CNY Mn)

19.000

Other borrowings (CNY Mn)

6.7——

Other borrowings, non-current, maturity split not disclosed (CNY Mn)

—19.8—

Analyst Conclusions

Management guidance

There is no quantitative guidance. The FY2025 outlook (30 Mar 2026) is qualitative. It expects more competitive and challenging wholesale and consumer pharmaceutical markets, and says the Group will focus on improving production and distribution capabilities. There is no consensus estimate: zero analysts cover the stock.

Bull case (three arguments)

  1. Liquidation-to-recapitalisation optionality. HKEX has granted until 1 Jan 2028. A strategic investor could buy into a licensed Sichuan drug manufacturer and distributor with a listed platform. The scheme allows shortfalls to be settled in shares, so dilutive recapitalisation is mechanically available.

  2. Asset backing exceeds market cap on a gross basis. PP&E (RMB27.5m), the property project (RMB39.9m), net receivables (RMB52.2m) and inventory (RMB19.7m) total about RMB139m. That compares with an equity value of about RMB33m, although these assets sit behind about RMB206m of debt.

  3. Revenue resilience. Revenue held at about RMB86–87m through two crisis years, and there are proven receivable recoveries (RMB11.6m ECL reversal in FY2025). This suggests the PRC operations retain customer franchise if they can be financed.

Bear case (three arguments)

  1. Loss of the operating business. Receivers now control the assets of the holding company for 100% of revenue, and management cannot access the subsidiaries' books. Deconsolidation would leave a cash-less listed shell with about RMB160m of scheme obligations.

  2. Structural insolvency. FY2025 gross profit (RMB12.0m) does not cover overheads (RMB19.2m) or finance costs (RMB15.0m). Net liabilities widen by about RMB12–20m a year. VBP is a permanent margin headwind.

  3. Governance and track record. The company has had four late-results episodes, a disclaimer of opinion, failed related acquisitions proposed by the controller, D&O insurance gaps and three board-composition breaches. Equity holders rank behind secured creditors, scheme creditors and petitioning creditors.

Key catalysts and monitorables (next 12 months)

Date / windowCatalystWhy it matters
21 Oct 2026Adjourned winding-up petition hearing (Underdog Consulting, HK$8m)A winding-up order would likely end the equity story; dismissal is a resumption condition
Q4 2026Receivers' actions over Toyot Pa Shun assets: sale, settlement or releaseDetermines whether the Group keeps its operations
By 31 Dec 2026 (indicative)Next quarterly resumption update (Rule 13.24A)Disclosure of any resumption plan or investor
OngoingAppointment of a third INED and audit committee memberRequired for Rules 3.10(1) and 3.21 compliance
OngoingPublication of 2026 interim results (overdue)Evidence of regained control of records
Mar 2027FY2026 annual results deadlineRisk of further delay, deconsolidation accounting and audit modification
By 30 Jun 20272026 Scheme yearly payment (HK$10m)A further default would compound creditor action
1 Jan 2028HKEX delisting deadlineTerminal date for resumption

Concluding analyst verdict

Pa Shun International Holdings has no investment case in the conventional sense. It is a distressed shell whose only economic substance is a small Sichuan pharmaceutical distribution and generic-manufacturing operation, and that operation is now under the control of secured-creditor receivers. Five years of filings tell a consistent story. In FY2019, revenue was RMB845 million. By FY2021 that had collapsed to about RMB86 million, alongside heavy impairments on a stalled Chengdu property project and a failed, controller-originated Malaysian property acquisition. Defaulted retail bonds produced a cascade of winding-up petitions. A 19-month trading suspension followed, and in March 2024 a creditor scheme converted HK$231 million of claims into about RMB160 million of back-ended, zero-coupon obligations.

The scheme bought time but did not fix the economics. FY2025 gross profit of RMB12.0 million covers neither cash overheads nor the unwinding of the scheme liability. Gross margin has compressed to 13.8% under national volume-based procurement and a shift toward 4%-margin wholesale. Cash had fallen to RMB5.5 million by year-end, and equity was negative RMB148 million. The June 2026 rights issue raised under HK$7 million and was 30% unsubscribed: a clear market verdict. Within weeks, a HK$8 million loan default produced a winding-up petition, receivers took over the assets of the intermediate holding company of all revenue-generating subsidiaries, and the shares were suspended.

For equity holders, the realistic outcomes range from heavy dilution in a white-knight recapitalisation, at best, to delisting and liquidation, at worst. The latter is more probable on current evidence. No resumption plan, investor or settlement has been disclosed as of 30 September 2026. Verdict: uninvestable for fundamental investors; relevant only to distressed-debt or shell-value specialists. Key binary event: the 21 October 2026 petition hearing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAgeBackgroundSource

Yuan Hongbing (袁紅兵)

Chairman and Executive Director (sole ED)

ED from 28 Mar 2023; Chairman by 20 May 2024

46 (per FY2023 AR)

20+ years in investment, M&A and investment banking. Founder and chairman of Yuanchuang Capital (venture, M&A, restructuring, fund management). ED and CEO of Jintai Energy Holdings (HKEX: 2728) since 2019. ED of China Clean Energy Technology Group (HKEX: 2379), Oct 2022 – Mar 2023

FY2023 AR; 30 Sep 2026 announcement

Li Yan (李燕)

Independent Non-Executive Director; Chair of Audit, Remuneration and CG Committees

10 Mar 2023

47 (FY2023 AR)

Accounting bachelor's from Wuhan Institute of Chemical Technology (2000). PRC CPA since 2002. CFO of several listed companies; restructuring and IPO experience

FY2023 AR

Wong Tung Yuen (王東源)

Independent Non-Executive Director

20 May 2024

Not disclosed in reviewed documents

—

FY2024 results

Board & Management Changes

DateChangeContextSource

10 Mar 2023

INEDs Luo Ke and Ding Qing resign; Li Yan and Khor Khie Liem Alex appointed

Remediation during the 2022–23 suspension

FY2023 AR

16 Mar 2023

NED Zhang Xiongfeng resigns

Held 34.8m shares (2.36%) plus 10m options

FY2023 AR

28 Mar 2023

Yuan Hongbing appointed ED

Restructuring-oriented investor-executive

FY2023 AR

1 Oct 2023

Company secretary changes: So Wing Chun replaced by Lam Yuen Ling Eva (BMI Listed Corporate Services)

Outsourced secretarial function

FY2023 AR

26 Oct 2023

ED Shen Shun resigns

Long-serving ED (held 3.5m shares)

FY2023 AR

22 Feb 2024

Chairman Xiao Kai, CEO Feng Junzheng, NEDs Zhang Tong and Chen Yunwei, and INED Cao Lei all retire at AGM

Left the board below Listing Rule minimums; no chairman or CEO

FY2023 AR

20 May 2024

Ma Qinghai (CEO), Chen Zhongzheng and Zhou Jinkai (NEDs), Lowe Chun Yip and Wong Tung Yuen (INEDs) appear on board; Yuan becomes Chairman

Re-compliance with board composition rules

Board list (20 May 2024); FY2024 results

26 Jun 2025

INED Khor Khie Liem Alex retires

—

2025 Interim Report

H1 2026 (date not confirmed)

Fang Shuai (房帥) joins as NED

Listed as NED on 26 Jun 2026

Winding-up petition announcement (26 Jun 2026)

16 Jun 2026

Executive director resignation, most likely Ma Qinghai: he is absent from the 26 Jun 2026 director list

Coincides with the rights-issue completion

etnet announcement index; 26 Jun 2026 announcement

7 Jul 2026

Directors retire at adjourned AGM. Board reduced to Yuan Hongbing, Li Yan and Wong Tung Yuen (NEDs Chen Zhongzheng, Zhou Jinkai and Fang Shuai, and INED Lowe Chun Yip, no longer listed)

Listing Rule non-compliance announced

etnet index; 16 Jul 2026 announcement director list

Executive Leadership Team

NameRoleAge (FY2023 AR)Background

Li Xiaoduo (李小多)

Manager, manufacturing operations (production and quality control)

56

Joined 1998; deputy GM of Wuhan Baixin Holdings Group; formerly with Chengdu Di Kang Pharmaceuticals and Chongqing Oriental Pharmaceutical; TCM graduate, Chengdu College of TCM (1994)

Tang Zaixiu (唐再秀)

Head of accounting

45

Joined Chengdu Kexun in 1999; accounting graduate of Chongqing Technology and Business University (2007)

Lam Yuen Ling Eva

Company Secretary (outsourced)

—

30+ years in company secretarial work; director at BMI Listed Corporate Services

Major Shareholders

HolderShares% of issued (approx.)NotesSource

Chen Yenfei, via Praise Treasure Limited (嘉寶有限公司)

1,129,560,000

56.7 (derived, post-rights)

Founder and controlling shareholder

Rights-issue results (17 Jun 2026)

Chen Yenfei, direct

13,560,000

0.7 (derived)

—

Same

Chen Yenfei total

1,143,120,000

57.4 (derived)

753,040,000 of these shares are pledged; original chargee's rights assigned to Win Win International Strategic Investment Funds SPC (Win Win Stable No.3 Fund SP); receivers (RSM: Osman Mohammed Arab and Lai Wing Lun) appointed 27 Jul 2022

FY2023 AR; rights-issue results

Zhongtai Innovation Capital Management Ltd

753,040,000 (security interest / investment manager)

51.05 (pre-rights)

Disclosed as investment manager in respect of the charged shares

FY2023 AR

Zhang Xiongfeng (former NED)

34,814,000

2.36 (pre-rights, as of FY2023)

—

FY2023 AR

Public / others

Remainder

about 40

24 valid acceptances in the rights issue

Rights-issue results

Competitive Landscape

Key Competitors

CompetitorTickerSegment overlapRelative positioning vs Pa Shun

Sinopharm Group

1099.HK

Distribution (national, hospital)

China's largest pharma distributor; dominant hospital network

Shanghai Pharmaceuticals

2607.HK / 601607.SH

Distribution and manufacturing

Integrated national player

China Resources Pharmaceutical

3320.HK

Distribution and manufacturing

State-backed integrated player

Jointown Pharmaceutical

600998.SH

Distribution (including county and rural channels)

Largest private distributor; strong in lower-tier markets, Pa Shun's rural niche

China Meheco

600056.SH

Distribution

State-owned distributor

Huadong Medicine

000963.SZ

Distribution and manufacturing

Regional (Zhejiang) integrated player

Sichuan Kelun Pharmaceutical

002422.SZ

Generic manufacturing (Sichuan)

Major Sichuan-based generic and infusion maker; VBP participant

Local Sichuan distributors and county-level tender winners (various, unlisted)

—

Rural institutional distribution

Direct competitors for provincial tenders

Competitor Detail

MetricPa Shun

Revenue (CNY Mn)

86.8

Revenue growth (%)

0.3

Gross margin (%)

13.8

Net margin (%)

-18.3

Recent Developments

--

Company Snapshot

$12.1M

Revenue

108

Employees

2011

Founded

Wanchai, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Licensed, operating PRC platform. The Group holds distribution and GMP manufacturing operations generating RMB86.8m of revenue (FY2025). Revenue was stable year on year (+0.3%).
  • Manufacturing segment margin. Manufacturing earned about 38% gross margin on segment revenue in FY2025 (RMB6.2m on RMB16.3m), well above distribution's 8%.
  • Long-tenured operating staff. The manufacturing head has served since 1998 and the head of accounting since 1999 (FY2023 AR), giving operational continuity.
  • Major legacy liabilities restructured. The 2024 scheme discharged HK$230.8m of claims into zero-coupon obligations. RMB17.6m of gain was recognised (FY2024).
  • Demonstrated cost discipline. Selling expenses fell 42.2% in FY2025 and administrative expenses have been flat at about RMB14.5m since FY2024.
  • Real-asset backing. PP&E of RMB27.5m and the property project of RMB39.9m (FY2025) provide collateral and recovery value, though RMB24.0m of land and buildings is already pledged.
  • Controlling shareholder participation. Mr. Chen took up his full rights entitlement in June 2026 (holding rose from 766.6m to 1,143.1m shares).

Weaknesses

  • Balance-sheet insolvency. Net liabilities of RMB148.0m at 31 Dec 2025, negative every year-end since FY2021.
  • Minimal liquidity. Cash of RMB5.5m versus RMB117.9m of current liabilities; current ratio 0.85x (FY2025).
  • Finance costs exceed gross profit. RMB15.0m of finance costs against RMB12.0m of gross profit (FY2025).
  • Weak receivable quality. RMB246.6m of a RMB298.8m gross receivable book is provisioned. RMB28.0m of the net book is aged over six months (FY2025).
  • Governance failures. Repeated late results (FY2021, FY2022, FY2024 and 2026 interim). Directors were uninsured from Jun 2021 to Dec 2023 and again from 7 Dec 2024. The FY2021 audit carried a disclaimer of opinion. The board has been non-compliant three times (2024, 2026 and currently).
  • Customer and supplier concentration. Two customers made up 24.9% of FY2025 revenue. In FY2023, the top supplier provided 43.3% of purchases.
  • No R&D or product differentiation. No disclosed R&D, patents or named brands.

Opportunities

  • Restructuring optionality. If a white-knight investor emerges, the Group's licences and listing status could be recapitalised. HKEX allows until 1 Jan 2028.
  • VBP volume. Inclusion guarantees procurement volumes and could lift utilisation at the Sichuan plant if costs can be cut.
  • Rural healthcare investment. China continues to invest in county-level healthcare. The Group's rural tender channel was 33.7% of FY2025 revenue.
  • Monetisation of non-core property. Selling the RMB39.9m property project (via Chengdu Yiming) could fund scheme obligations.
  • Recovery of over-provisioned receivables. The RMB11.6m ECL reversal in FY2025 shows collections on previously impaired debts are possible.
  • Scheme flexibility. Unpaid scheme amounts can be settled in shares rather than cash (FY2025 Note 12), which reduces cash pressure at the cost of dilution.

Threats

  • Winding-up petition. Underdog Consulting is pursuing a HK$8m loan default; the hearing is on 21 Oct 2026. A winding-up order would remove management control of the listed company.
  • Receivership of operating assets. EY receivers control Toyot Pa Shun's secured assets, which cover 100% of revenue (30 Sep 2026 update). Deconsolidation would leave the listed shell with no business.
  • Delisting. The HKEX 18-month deadline is 1 Jan 2028. The Exchange may also shorten it.
  • Scheme default cascade. The HK$10m yearly payments for 2025–2028 are unfunded. The 2024 payment (HK$5m) was itself only covered by the creditor-seized deposit.
  • Further VBP price cuts. These could compress manufacturing margins further.
  • PRC litigation. A RMB4.66m design-fee suit against Chengdu Yiming is pending (FY2024 Note 13). Management considers settlement remote, but the suit remains outstanding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025Announces delay of FY2024 annual results HKEX announcement (28 Apr 2025, referencing 31 Mar)Third late-results episode since 2022
1 Apr 2025Trading suspended pending FY2024 results SameLiquidity and credibility hit
28 Apr 2025Board meeting set for 30 Apr 2025; suspension continues HKEX (28 Apr 2025)—
30 Apr 2025FY2024 results: revenue RMB86.6m (–33.1%), loss RMB15.3m, net liabilities RMB136.0m; going-concern material uncertainty FY2024 results announcementConfirms post-scheme loss-making
2 May 2025Trading resumes FY2024 results announcement—
27 May 2025AGM circular: general mandates, re-election, auditor reappointment HKEX circular (27 May 2025)Routine
26 Jun 2025AGM; INED Khor Khie Liem Alex retires 2025 Interim ReportBoard shrinks
30 Jul 2025Board meeting notice for H1 2025 results HKEX (30 Jul 2025)—
31 Jul 2025Profit warning: H1 2025 net loss of no more than RMB10m vs H1 2024 profit of about RMB35m (which included about RMB47.4m one-off restructuring gain) Profit warning (31 Jul 2025)Confirms absence of underlying profitability
11 Aug 2025H1 2025 interim results published Interim results (11 Aug 2025)–
2025 (date n/d)Substantial portion of products enter national VBP FY2025 MD&AFY2025 gross margin falls to 13.8%
17 Mar 2026Board meeting notice for FY2025 results HKEX (17 Mar 2026)—
24 Mar 2026Profit warning for FY2025 (third-party summary cites RMB20–27m expected loss) etnet indexDiscrepancy vs audited RMB15.9m loss
30 Mar 2026FY2025 results: revenue RMB86.8m, loss RMB15.9m, net liabilities RMB148.0m, cash RMB5.5m; going-concern paragraphDeepening insolvency
16 Apr 2026Proposed 1-for-2 non-underwritten rights issue etnet indexEmergency equity raise
28 Apr 2026Announcement of shareholder requisition for an EGM EGM dissolution announcement (26 Jun 2026)Board-control contest signal
11 May 2026Rights issue prospectus Rights-issue results—
17 May 2026EGM circular (requisitioned meeting) Same—
26 May 2026Rights issue acceptance deadline: 69.91% accepted Rights-issue resultsPartial support; controller took up entitlement
8 Jun 2026AGM notice; repurchase mandate itiger summaryRoutine
10 Jun 2026Rights issue unconditional; gross HK$6.99m Rights-issue resultsMarginal liquidity relief
16 Jun 2026Executive director resignation; supplemental AGM circular for re-election of directors etnet indexManagement turnover
17 Jun 2026Rights-issue results published—
26 Jun 2026Requisitioned EGM in Chengdu dissolved (no quorum within 30 minutes) EGM dissolution announcementContest unresolved
26 Jun 2026Underdog Consulting Limited files winding-up petition in the HK High Court over an unpaid HK$8m loan due 10 Nov 2024; hearing set for 16 Sep 2026 Inside information (26 Jun 2026)Existential legal threat
30 Jun 2026AGM adjourned etnet index—
2 Jul 2026Trading halted, then suspended; EY's Kam Chung Hang and Zou Wenjin appointed receivers and managers over secured assets of Toyot Pa Shun Medicine Factory Co. Ltd. Inside information (2 Jul 2026), via third-party summary; 30 Sep 2026 updateLoss of control over 100% of revenue-generating assets
7 Jul 2026Adjourned AGM poll results; directors retire; Listing Rule non-compliance etnet indexBoard reduced to three
14–16 Jul 2026HKEX resumption guidance; delisting deadline 1 Jan 2028 Resumption guidance (16 Jul 2026)Formal delisting clock
21 Jul 2026Supplemental announcement on dissolved requisitioned EGM etnet index—
24 Aug 2026Expected delay of 2026 interim results and report 30 Sep 2026 updateLack of access to subsidiaries' records
1 Sep 2026Further inside-information announcement on the winding-up petition and loan default etnet index–
16 Sep 2026Petition hearing adjourned to 21 Oct 2026 30 Sep 2026 updateNext binary legal event
30 Sep 2026First quarterly resumption update; no resumption plan detail 30 Sep 2026 updateLittle progress

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 85.9 Mn in FY2021 to CNY 86.8 Mn in FY2025.
Pa Shun International Holdings Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue85.971.8129.486.686.8
Cost of goods sold—58.5100.169.574.8
Gross profit—13.329.317.112

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.